比较普瑞巴林与加巴喷丁治疗原发性三叉神经痛HLA-B^(*)1502等位基因阳性患者的安全性和疗效  

Comparison of the safety and efficacy between pregabalin and gabapentin in the treatment of patients with primary trigeminal neuralgia with positive HLA-B^(*)1502 allele

作　　者：姚传玉[1] 任玉娥[2] Yao Chuanyu;Ren Yu'e(Department of Pain Management,People's Hospital of Qingxian,Cangzhou City,Hebei Province 062650,China;Department of Pain Management,the Second Hospital of Hebei Medical University,Shijiazhuang City,Hebei Province 050000,China)

机构地区：[1]河北省青县人民医院疼痛科(原于河北医科大学第二医院疼痛科进修),河北省沧州市062650 [2]河北医科大学第二医院疼痛科,石家庄市050000

出　　处：《中华疼痛学杂志》2021年第1期42-47,共6页Chinese Journal Of Painology

摘　　要：目的比较普瑞巴林与加巴喷丁治疗原发性三叉神经痛HLA-B^(*)1502等位基因阳性患者的临床疗效和安全性。方法收集2018年1月至2019年1月在河北医科大学第二医院疼痛科就诊的原发性三叉神经痛患者76例,视觉模拟评分(VAS)>6分,HLA-B^(*)1502等位基因检测均为阳性。按照随机数字表法将其随机分为普瑞巴林组与加巴喷丁组,每组38例。普瑞巴林组口服普瑞巴林75 mg/次,2次/d,加巴喷丁组口服加巴喷丁0.3 g/次,3次/d,两组疗程均为28 d。分别于治疗前及治疗后7、14、28 d时测定VAS评分,采用匹兹堡睡眠质量指数(PSQI)问卷对两组患者进行睡眠质量评价,于治疗后28 d时评定临床疗效。记录治疗期间皮疹等不良反应。结果与治疗前比较,两组治疗后7、14、28 d时VAS评分和PSQI评分均降低(P均<0.05);与加巴喷丁组比较,普瑞巴林组治疗后28 d时VAS评分降低更明显,治疗后14、28 d时PSQI评分降低亦较明显(P均<0.05)。普瑞巴林组优效16例,良效15例,差效6例,治疗总有效率为81.6%;加巴喷丁组优效13例,良效12例,差效10例,治疗总有效率为65.8%,与加巴喷丁组比较,普瑞巴林组治疗总有效率较高(P<0.05)。两组不良反应发生率比较差异均无统计学意义(P均>0.05)。结论加巴喷丁与普瑞巴林对原发性三叉神经痛HLA-B^(*)1502等位基因阳性患者均有疗效,且不良反应相当,但普瑞巴林的镇痛作用更强。Objective To compare the efficacy and safety between pregabalin and gabapentin in the treatment of patients with primary trigeminal neuralgia with positive HLA-B^(*)1502 allele.Methods Seventy-six patients of primary trigeminal neuralgia with positive HLA-B^(*)1502 allele,visual analogue scale(VAS)>6,in the Department of Pain Management of the Second Hospital of Hebei Medical University,were enrolled from January 2018 to January 2019.The patients were randomly divided into two groups:pregabalin group(n=38)and gabapentin group(n=38),in accordance with the random number table.The patients received oral pregabalin 75 mg,twice one day,or gabapentin 0.3 g,three times one day for 28 days in the two groups respectively.VAS and Pittsburgh sleep quality index(PSQI)were determined before the treatment and at 7,14,and 28 days after the treatment.The clinical efficacy was evaluated at 28 days after the treatment.The incidences of adverse reactions were recorded during the treatment,including skin reaction,ataxia,dizziness,and leukopenia.Results Compared with the pretreatment,VAS and PSQI were significantly decreased at 7,14,28 days after the treatment in the two groups(all P<0.05).Compared with the gabapentin group,VAS was significantly decreased at the 28 days after the treatment in the pregabalin group;PSQI was significantly decreased at the 14,28 days after the treatment in the pregabalin group(all P<0.05).There were 16 cases with effective effects,15 cases with good effects,6 cases with poor effects in the pregabalin group,13 cases with effective effects,12 cases with good effects,10 cases with poor effects in the gabapentin group respectively.The total effective rate of the pregabalin group was significantly higher than that in the gabapentin group at the 28 days after the treatment(81.6%vs.65.8%,P<0.05).There were no significant differences in the incidences of adverse reactions related to drug such as ataxia,dizziness,and leukopenia(all P>0.05).There were no exanthema and skin reaction.Conclusions Gabapentin and prega

关 键 词：普瑞巴林 加巴喷丁 三叉神经痛 安全性 治疗效果 

分 类 号：R745.11[医药卫生—神经病学与精神病学]